- Home
- SKYE vs VTGN Comparison
SKYE vs VTGN Comparison
Compare SKYE & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- VTGN
- Stock Information
- Founded
- SKYE 2012
- VTGN 1998
- Country
- SKYE United States
- VTGN United States
- Employees
- SKYE N/A
- VTGN N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- SKYE Health Care
- VTGN Health Care
- Exchange
- SKYE Nasdaq
- VTGN Nasdaq
- Market Cap
- SKYE 80.7M
- VTGN 82.7M
- IPO Year
- SKYE N/A
- VTGN N/A
- Fundamental
- Price
- SKYE $2.43
- VTGN $2.72
- Analyst Decision
- SKYE Buy
- VTGN
- Analyst Count
- SKYE 7
- VTGN 0
- Target Price
- SKYE $18.67
- VTGN N/A
- AVG Volume (30 Days)
- SKYE 136.4K
- VTGN 157.5K
- Earning Date
- SKYE 03-21-2025
- VTGN 02-13-2025
- Dividend Yield
- SKYE N/A
- VTGN N/A
- EPS Growth
- SKYE N/A
- VTGN N/A
- EPS
- SKYE N/A
- VTGN N/A
- Revenue
- SKYE N/A
- VTGN $698,000.00
- Revenue This Year
- SKYE N/A
- VTGN N/A
- Revenue Next Year
- SKYE N/A
- VTGN N/A
- P/E Ratio
- SKYE N/A
- VTGN N/A
- Revenue Growth
- SKYE N/A
- VTGN N/A
- 52 Week Low
- SKYE $2.31
- VTGN $2.22
- 52 Week High
- SKYE $17.65
- VTGN $5.74
- Technical
- Relative Strength Index (RSI)
- SKYE 40.00
- VTGN 48.70
- Support Level
- SKYE $2.40
- VTGN $2.59
- Resistance Level
- SKYE $2.88
- VTGN $2.84
- Average True Range (ATR)
- SKYE 0.24
- VTGN 0.19
- MACD
- SKYE -0.02
- VTGN 0.01
- Stochastic Oscillator
- SKYE 3.74
- VTGN 57.81
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.